Impact of Solid Minor Histologic Subtype in Postsurgical Prognosis of Stage I Lung Adenocarcinoma Tianxiang Chen, MD, PhD, Jizhuang Luo, MD, Haiyong.

Slides:

Advertisements

Similar presentations

The Correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS)

Advertisements

Elizabeth A. David, MD, David T

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Nathan M. Mollberg, DO,

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Thomas J. Birdas, MD, Richard P. M

Outcomes of Sublobar Resection Versus Lobectomy for Stage I Non–Small Cell Lung Cancer: A 13-Year Analysis Amgad El-Sherif, MD, William E. Gooding, MS,

Surgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival Elizabeth A. David, MD, Robert J. Canter,

Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database Daniel J. Boffa,

Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,

Long Interspersed Nucleotide Element 1 Hypomethylation Is Associated With Poor Prognosis of Lung Adenocarcinoma Koei Ikeda, MD, PhD, Kenji Shiraishi,

Zhiqiang Xue, MD, Fengying Wu, MD, Karlyn E

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

The Effectiveness of Postoperative Radiotherapy in Patients With Completely Resected Thymoma: A Meta-Analysis Dong Zhou, MD, Xu-Feng Deng, MD, Quan-Xing.

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy

Long-Term Survival After Arterial Versus Atrial Switch in d-Transposition of the Great Arteries Alexander Kiener, MD, MPH, Michael Kelleman, MSPH, Courtney.

Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non- Small Cell Lung Cancer Paul J. Speicher, MD, Zachary W. Fitch,

Prognostic Variables in Thoracic Esophageal Squamous Cell Carcinoma

The Model for End-Stage Liver Disease (MELD) Predicts Early and Late Outcomes of Cardiovascular Operations in Patients With Liver Cirrhosis Naoto Morimoto,

David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L

Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease Brendon M. Stiles, MD, Farooq Mirza, MD, Anthony Coppolino, MD, Jeffrey L. Port,

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Neither Maximum Tumor Size nor Solid Component Size Is Prognostic in Part-Solid Lung Cancer: Impact of Tumor Size Should Be Applied Exclusively to Solid.

Loretta Erhunmwunsee, MD, Brian C

Osteopontin-Expressing Macrophages in Non-Small Cell Lung Cancer Predict Survival Yue Li, MD, Bing-sheng Sun, MD, PhD, Baoxiang Pei, MD, Chen-guang Li,

Importance of Ground Glass Opacity Component in Clinical Stage IA Radiologic Invasive Lung Cancer Aritoshi Hattori, MD, Takeshi Matsunaga, MD, Kazuya.

Survival of Patients With or Without Symptoms Undergoing Potentially Curative Resections for Primary Lung Cancer Andrea R.G. Sheel, BS (Hons), MBChB,

Readmission to Intensive Care Unit After Initial Recovery From Major Thoracic Oncology Surgery Suk-Won Song, MD, Hyun-Sung Lee, MD, PhD, Jae-Hyun Kim,

Thomas J. Birdas, MD, Richard P. M

Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma Shinsuke Sasada, MD, PhD, Yoshihiro Miyata, MD, PhD,

Influence of Cigarette Smoking on Survival and Tumor Invasiveness in Clinical Stage IA Lung Adenocarcinoma Ryo Maeda, MD, Junji Yoshida, MD, Genichiro.

Age-Dependent Gender Disparities in Post Lung Transplant Survival Among Patients With Idiopathic Pulmonary Fibrosis Shahid I. Sheikh, MD, Don Hayes,

Radical Lymph Node Dissection in Primary Esophagectomy for Esophageal Squamous Cell Carcinoma Chen-Sung Lin, MD, PhD, Chih-Tao Cheng, MD, DrPH, Chao-Yu.

Impact of Blood Product Transfusion on Short and Long-Term Survival After Cardiac Surgery: More Evidence Balu Bhaskar, MD, FCICM, Joel Dulhunty, PhD,

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

The Prognostic Value of the Number of Negative Lymph Nodes in Esophageal Cancer Patients After Transthoracic Resection Po-Kuei Hsu, MD, Chien-Sheng Huang,

Lei Yu, MD, Tianxiang Gu, MD, PhD, Zongyi Xiu, MD, PhD

Andrew P. Dhanasopon, MD, Michelle C. Salazar, MD, Jessica R

Brendon M. Stiles, MD, Mohamed K. Kamel, MD, Sebron W

A Comprehensive Investigation of Molecular Features and Prognosis of Lung Adenocarcinoma with Micropapillary Component Yang Zhang, MD, Rui Wang, PhD,

Tumor Spread through Air Spaces Affects the Recurrence and Overall Survival in Patients with Lung Adenocarcinoma >2 to 3 cm Chenyang Dai, MD, Huikang.

Interaction of Donor and Recipient Age: Do Older Heart Transplant Recipients Require Younger Hearts? Malini Daniel, MD, Carol Chen, MD, Jennifer Chung,

Surgical Therapy for Bilateral Multiple Primary Lung Cancer

High Expression of p300 Has an Unfavorable Impact on Survival in Resectable Esophageal Squamous Cell Carcinoma Yong Li, MD, Hao-Xian Yang, MD, Rong-Zhen.

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko.

Characteristics of Malignant Pleural Mesothelioma in Women

Posttransplant Outcomes Among Septuagenarians Bridged to Transplantation With Continuous-Flow Left Ventricular Assist Devices Shinichi Fukuhara, MD,

Jonathan D. Spicer, MD, PhD, Jitesh B. Shewale, BDS, PhD, David B

Clinicopathologic Features and Computed Tomographic Findings of 52 Surgically Resected Adenosquamous Carcinomas of the Lung Yukio Watanabe, MD, Koji.

Refining the Nodal Staging for Esophageal Squamous Cell Carcinoma Based on Lymph Node Stations Jun Peng, MD, Wen-Ping Wang, MD, Ting Dong, MD, Jie Cai,

Comparison of Prognosis of Solid and Part-Solid Node-Negative Adenocarcinoma With the Same Invasive Component Size Kyung Wook Shin, MD, Sukki Cho, MD,

Comparison of Neoadjuvant Chemotherapy Followed by Surgery to Upfront Surgery for Thymic Malignancy Samina Park, MD, In Kyu Park, MD, PhD, Young Tae.

Prognosis of Patients With Pathologic T0 N+ Esophageal Squamous Cell Carcinoma After Chemoradiotherapy and Surgical Resection: Results From a Nationwide.

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study Hans Rostad, MD, PhD, Trond-Eirik Strand, MD, Anne Naalsund, MD, Jarle Norstein,

The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,

Neal S Goldstein, MD The Annals of Thoracic Surgery

Effect of Formalin Fixation on Tumor Size Determination in Stage I Non-Small Cell Lung Cancer Po-Kuei Hsu, MD, Hsu-Chih Huang, MD, Chih-Cheng Hsieh,

Role of Positron Emission Tomography/Computed Tomography Findings for Adjuvant Chemotherapy Indications in Stage T1b-2aN0M0 Lung Adenocarcinoma Shinsuke.

Survival Benefits of Postoperative Chemoradiation for Lymph Node–Positive Esophageal Squamous Cell Carcinoma Po-Kuei Hsu, MD, Chien-Sheng Huang, MD,

Lobectomy for Lung Cancer at Veterans Administration Medical Center Versus Academic Medical Center Travis Geraci, MD, Vanessa Baratta, MD, John Young,

Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma Tomoharu Yoshiya, MD, Takahiro Mimae, MD, PhD, Yasuhiro.

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Detailed Analysis of Prognostic Factors in Primary Esophageal Small Cell Carcinoma Wei-Wei Chen, MD, Feng Wang, MD, PhD, ShaoBin Chen, MD, Luhua Wang,

Induction Chemoradiation Is Not Superior to Induction Chemotherapy Alone in Stage IIIA Lung Cancer Asad A. Shah, MD, Mark F. Berry, MD, Ching Tzao, MD,

Presentation transcript:

Impact of Solid Minor Histologic Subtype in Postsurgical Prognosis of Stage I Lung Adenocarcinoma Tianxiang Chen, MD, PhD, Jizhuang Luo, MD, Haiyong Gu, MD, Yu Gu, MD, Qingyuan Huang, MD, Yiyang Wang, MD, Jiajie Zheng, MD, Yunhai Yang, MD, Haiquan Chen, MD The Annals of Thoracic Surgery Volume 105, Issue 1, Pages 302-308 (January 2018) DOI: 10.1016/j.athoracsur.2017.08.018 Copyright © 2018 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Survival curves for (A) disease-free survival and (B) overall survival for stage I invasive lung adenocarcinoma patients according to the eighth TNM staging (p values from log rank test): lepidic (LEP) (green lines); acinar (ACN) (blue lines); papillary (PAP) (purple line); micropapillary (MIP) (gold lines); and solid (SOL) (red lines). The Annals of Thoracic Surgery 2018 105, 302-308DOI: (10.1016/j.athoracsur.2017.08.018) Copyright © 2018 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Survival curves for (A, C) disease-free survival and (B, D) overall survival according to percentage of solid (S) component presented in tumor tissue. Survival curves for (A, B) stage IA patients and (C, D) stage IB patients according to eighth TNM staging project (p values from log rank test). Green lines indicate solid absent; blue lines indicate solid minor; and red lines indicate solid predominant. (vs. = versus.) The Annals of Thoracic Surgery 2018 105, 302-308DOI: (10.1016/j.athoracsur.2017.08.018) Copyright © 2018 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 Survival curves for (A, C) disease-free survival and (B, D) overall survival according to treatment arm—adjuvant chemotherapy (blue lines) versus surgery alone (red lines)—of patients in (A, B) solid predominant group and (C, D) solid minor group (p values from log rank test). (ACT = adjuvant chemotherapy; CI = confidence interval; HR = hazard ratio.) The Annals of Thoracic Surgery 2018 105, 302-308DOI: (10.1016/j.athoracsur.2017.08.018) Copyright © 2018 The Society of Thoracic Surgeons Terms and Conditions